罕见中枢神经系统胚胎性肿瘤分子诊断分型对治疗的影响:国际回顾性研究
本研究对原诊断为CNS-PNET的肿瘤样本行DNA甲基化芯片分析(n=307),并纳入66例CNS NB-FOXR2病例,汇总292例临床数据。分子分型后CNS NB-FOXR2患者5年PFS 63%±7%、OS 85%±5%,ETMR与HGG预后最差。
要点
- DNA甲基化分型可将原CNS-PNET重新分类为ETMR、HGG、CNS NB-FOXR2等不同实体。
- CNS NB-FOXR2患者经CSI联合化疗后预后较好,5年OS达85%±5%。
- ETMR与HGG患者5年OS仅24%±6%与25%±7%,亟需新治疗策略。
核心结论
- 基于DNA甲基化分型后,原CNS-PNET患者的预后差异显著,CNS NB-FOXR2治疗反应良好,ETMR与HGG预后仍差。
研究设计与样本
- 国际回顾性研究,对原诊断CNS-PNET的307例肿瘤样本行DNA甲基化芯片分析,另纳入66例CNS NB-FOXR2病例,汇总292例临床数据进行描述性分析。
主要发现
- CNS NB-FOXR2患者5年PFS 63%±7%、OS 85%±5%(n=63),42例无进展生存者中35例接受过 upfront CSI 和化疗。
- ETMR患者5年PFS 18%±6%、OS 24%±6%;HGG患者5年PFS 22%±7%、OS 25%±7%。
临床怎么用
- 对原诊断为CNS-PNET的肿瘤应行DNA甲基化分型以明确具体实体,指导预后判断与治疗选择。
- CNS NB-FOXR2患者可考虑基于CSI的标准风险方案,但需前瞻性评估。
- ETMR与HGG患者现有治疗下预后差,应纳入新型治疗临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Only few data are available on treatment-associated behavior of distinct rare CNS embryonal tumor entities previously treated as "CNS-primitive neuroectodermal tumors" (CNS-PNET). Respective data on specific entities, including CNS neuroblastoma, FOXR2 activated (CNS NB-FOXR2), and embryonal tumors with multilayered rosettes (ETMR) are needed for development of differentiated treatment strategies. METHODS: Within this retrospective, international study, tumor samples of clinically well-annotated patients with the original diagnosis of CNS-PNET were analyzed using DNA methylation arrays (n = 307). Additional cases (n = 66) with DNA methylation pattern of CNS NB-FOXR2 were included irrespective of initial histological diagnosis. Pooled clinical data (n = 292) were descriptively analyzed. RESULTS: DNA methylation profiling of "CNS-PNET" classified 58 (19%) cases as ETMR, 57 (19%) as high-grade glioma (HGG), 36 (12%) as CNS NB-FOXR2, and 89(29%) cases were classified into 18 other entities. Sixty-seven (22%) cases did not show DNA methylation patterns similar to established CNS tumor reference classes. Best treatment results were achieved for CNS NB-FOXR2 patients (5-year PFS: 63% ± 7%, OS: 85% ± 5%, n = 63), with 35/42 progression-free survivors after upfront craniospinal irradiation (CSI) and chemotherapy. The worst outcome was seen for ETMR and HGG patients with 5-year PFS of 18% ± 6% and 22% ± 7%, and 5-year OS of 24% ± 6% and 25% ± 7%, respectively. CONCLUSION: The historically reported poor outcome of CNS-PNET patients becomes highly variable when tumors are molecularly classified based on DNA methylation profiling. Patients with CNS NB-FOXR2 responded well to current treatments and a standard-risk CSI-based regimen may be prospectively evaluated. The poor outcome of ETMR across applied treatment strategies substantiates the necessity for evaluation of novel treatments.
引用
- von Hoff K, Haberler C, Schmitt-Hoffner F, et al. Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro Oncol. 2021. PMID: 34077956. doi:10.1093/neuonc/noab136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。